Phenylalanine kinetics differ between formula-fed and human milk-fed preterm infants

Pauline B Darling1, Michael Dunn, G Sarwar Gilani

  • 1Research Institute, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. darlingp@smh.toronto.on.ca

The Journal of Nutrition
|October 7, 2004
PubMed

Insights

Formula-fed preterm infants show reduced phenylalanine catabolism, leading to higher plasma levels compared to breastfed infants. This suggests impaired amino acid metabolism in formula-fed infants.

Area of Science:

  • Biochemistry
  • Neonatology
  • Nutritional Science

Background:

  • Infants fed casein-dominant formulas exhibit higher plasma phenylalanine and tyrosine than those fed mother's milk.
  • Formula-fed preterm infants demonstrate a reduced capacity to degrade threonine compared to breastfed infants.

Purpose of the Study:

  • To investigate phenylalanine catabolism in preterm infants fed formulas with varying whey:casein ratios compared to mother's milk.
  • To determine if formula composition affects phenylalanine metabolism and plasma concentrations in preterm infants.

Main Methods:

  • Utilized a [1-(13)C]phenylalanine tracer to measure phenylalanine oxidation via (13)CO(2) production in breath.
  • Compared plasma phenylalanine concentrations and oxidation rates in preterm infants fed different formula compositions (whey:casein 60:40, 40:60, 20:80) versus mother's milk.

Main Results:

  • Plasma phenylalanine concentrations significantly increased with higher casein content in formulas.
  • Formula-fed infants showed a positive correlation between phenylalanine intake and oxidation, but insufficient to prevent plasma level increases with high-casein formula.
  • Phenylalanine oxidation was significantly lower in formula-fed infants (30.7% of intake) compared to those fed mother's milk (39.1% of intake).

Conclusions:

  • Formula-fed preterm infants exhibit down-regulated in vivo catabolism of phenylalanine, contributing to elevated plasma concentrations.
  • Impaired catabolism of essential amino acids, including phenylalanine and threonine, may explain metabolic differences between formula-fed and breastfed preterm infants.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...